Rapid growth rate: A method of identifying node-negative breast cancer patients with a high risk of recurrence

Rapid Growth Rate

183 A DNA signature to identify high-risk small node-negative breast cancer patients

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)70214-7 ◽

2010 ◽

Vol 8 (3) ◽

pp. 111-112 ◽

Author(s):

E. Gravier ◽

G. Pierron ◽

A. Vincent-Salomon ◽

N. Gruel ◽

V. Raynal ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Node Negative ◽

Abstract P1-13-13: First planned efficacy analysis of the NNBC 3-Europe trial: Addition of docetaxel to anthracycline containing adjuvant chemotherapy in high risk node-negative breast cancer patients.

10.1158/0008-5472.sabcs12-p1-13-13 ◽

2012 ◽

Author(s):

C Thomssen ◽

EJ Kantelhardt ◽

C Meisner ◽

M Vetter ◽

M Schmidt ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Node Negative ◽

Efficacy Analysis ◽

DNA methylation profile predicts risk of recurrence in tamoxifen-treated, node-negative breast cancer patients

10.1200/jco.2004.22.14_suppl.525 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 525-525 ◽

Author(s):

S. Maier ◽

I. Nimmrich ◽

A. Marx ◽

S. Eppenberger-Castori ◽

F. Jaenicke ◽

...

Keyword(s):

Breast Cancer ◽

Dna Methylation ◽

Cancer Patients ◽

Methylation Profile ◽

Breast Cancer Patients ◽

Node Negative ◽

Risk Of Recurrence ◽

Dna Methylation Profile

DNA methylation profile predicts risk of recurrence in tamoxifen-treated, node-negative breast cancer patients

10.1200/jco.2004.22.90140.525 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 525-525

Author(s):

S. Maier ◽

I. Nimmrich ◽

A. Marx ◽

S. Eppenberger-Castori ◽

F. Jaenicke ◽

...

Keyword(s):

Breast Cancer ◽

Dna Methylation ◽

Cancer Patients ◽

Methylation Profile ◽

Breast Cancer Patients ◽

Node Negative ◽

Risk Of Recurrence ◽

Dna Methylation Profile

A Retrospective Review of Association between Clinico-Pathologic Prognostic Factors and Disease Outcome in Node-Positive or High-Risk Node Negative Breast Cancer Patients Treated with Adjuvant Cyclophosphamide, Doxorubicin Followed by Paclitaxel: A Venezuelan Study.

10.1158/0008-5472.sabcs-09-6056 ◽

2009 ◽

Author(s):

R. Vera-Gimón ◽

C. Sucre ◽

E. Arbona-Roche ◽

L. Vivas ◽

H. Salazar ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

High Risk ◽

Cancer Patients ◽

Retrospective Review ◽

Disease Outcome ◽

Breast Cancer Patients ◽

Node Negative ◽

Node Positive ◽

Phase III Randomized Comparison of Postoperative Adjuvant Chemotherapy with 2-Year Oral UFT (Uracil/Tegafur) versus Six-Cycle CMF (Cyclophosphamide/Methotrexate/5-Fluorouracil) in High-risk Node-Negative Breast Cancer Patients

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/28.1.77 ◽

1998 ◽

Vol 28 (1) ◽

pp. 77-80 ◽

Cited By ~ 10

Keyword(s):

Breast Cancer ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Phase Iii ◽

Breast Cancer Patients ◽

Postoperative Adjuvant Chemotherapy ◽

Node Negative ◽

Abstract P1-13-02: Analysis of the NNBC 3-Europe trial: Addition of docetaxel to anthracycline containing adjuvant chemotherapy in high risk node-negative breast cancer patients.

10.1158/0008-5472.sabcs12-p1-13-02 ◽

2012 ◽

Author(s):

Christoph Thomssen ◽

Eva-Johanna Kantelhardt ◽

Christoph Meisner ◽

Martina Vetter ◽

Marcus Schmidt ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Node Negative ◽

Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel.

10.1200/jco.2014.32.15_suppl.11107 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 11107-11107

Author(s):

Federico Rojo ◽

Ana Lluch ◽

Amparo Ruiz ◽

Manuel Ruiz-Borrego ◽

Agusti Barnadas ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Cancer Patients ◽

Weekly Paclitaxel ◽

Breast Cancer Patients ◽

Node Negative ◽

The Role of Tamoxifen in Treatment of High-Risk, Node-Negative Breast Cancer Patients: Results of a Phase III Intergroup Trial (SWOG 8897, INT-102)1

Clinical Breast Cancer ◽

10.1016/s1526-8209(11)70100-8 ◽

2000 ◽

Vol 1 (1) ◽

pp. 28-29

Keyword(s):

Breast Cancer ◽

High Risk ◽

Cancer Patients ◽

Phase Iii ◽

Breast Cancer Patients ◽

Node Negative ◽

Intergroup Trial

Report of toxicities from the multicenter, randomized NNBC 3-Europe trial: 6xFEC versus 3xFEC-3xDoc for high-risk node-negative breast cancer patients.

10.1200/jco.2010.28.15_suppl.554 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 554-554 ◽

Author(s):

C. Thomssen ◽

E. J. Kantelhardt ◽

K. Plueckhahn ◽

C. Veyret ◽

D. Augustin ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Node Negative ◽